Literature DB >> 31687255

Two Novel GATA1 Mutations in Transient Abnormal Myelopoiesis of Thai Neonates with Down Syndrome.

Kanokporn Chukua1, Chayanont Netsawang1, Kittipoom Padungthai1, Thanitchet Khetkham2, Piyaporn Chokevittaya3, Onapinya Poonjearansilp3, Sariya Prachuktum3, Sudatip Kositamongkol3, Wiliporn Techasatit3, Phakatip Silapamongkolkul3, Wallee Satayasai3, Tasama Pusongchai3, Pacharapan Surapolchai3, Kitiwan Rojnueangnit3.   

Abstract

Children with Down syndrome (DS) are 150 times more likely to develop acute myeloid leukemia (ML-DS), compared with those without. One risk factor is transient abnormal myelopoiesis (TAM). Somatic truncating GATA1 mutations are found in most TAM patients and are markers for future ML-DS. We identified two novel frameshift mutations in our seven newborns with DS and TAM: a heterozygous mutation of 17 nucleotide duplication (c.154_170 dup) and a heterozygous 9-nucleotide deletion combined with a 2-nucleotide insertion (c.150_158delins CT). Both mutations introduced a truncated GATA1 protein. Thus, neonates with DS and TAM require frequent ML-DS monitoring. © Thieme Medical Publishers.

Entities:  

Keywords:  Down syndrome; GATA1 mutation ; transient abnormal myelopoiesis

Year:  2019        PMID: 31687255      PMCID: PMC6824893          DOI: 10.1055/s-0039-1696971

Source DB:  PubMed          Journal:  J Pediatr Genet        ISSN: 2146-460X


  22 in total

1.  Down syndrome and GATA1 mutations in transient abnormal myeloproliferative disorder: mutation classes correlate with progression to myeloid leukemia.

Authors:  Rika Kanezaki; Tsutomu Toki; Kiminori Terui; Gang Xu; Runan Wang; Akira Shimada; Asahito Hama; Hirokazu Kanegane; Kiyoshi Kawakami; Mikiya Endo; Daisuke Hasegawa; Kazuhiro Kogawa; Souichi Adachi; Yasuhiko Ikeda; Shotaro Iwamoto; Takashi Taga; Yoshiyuki Kosaka; Seiji Kojima; Yasuhide Hayashi; Etsuro Ito
Journal:  Blood       Date:  2010-08-20       Impact factor: 22.113

2.  Familial dyserythropoietic anaemia and thrombocytopenia due to an inherited mutation in GATA1.

Authors:  K E Nichols; J D Crispino; M Poncz; J G White; S H Orkin; J M Maris; M J Weiss
Journal:  Nat Genet       Date:  2000-03       Impact factor: 38.330

3.  Parallel sequencing used in detection of mosaic mutations: comparison with four diagnostic DNA screening techniques.

Authors:  Anna Rohlin; Josephine Wernersson; Yvonne Engwall; Leif Wiklund; Jan Björk; Margareta Nordling
Journal:  Hum Mutat       Date:  2009-06       Impact factor: 4.878

4.  Transient myeloproliferative disorder in neonates without Down syndrome: case report and review.

Authors:  Alexandra Schifferli; Johann Hitzler; Deborah Bartholdi; Karl Heinimann; Sylvia Hoeller; Tamara Diesch; Thomas Kühne
Journal:  Eur J Haematol       Date:  2014-06-14       Impact factor: 2.997

5.  Perturbation of fetal liver hematopoietic stem and progenitor cell development by trisomy 21.

Authors:  Anindita Roy; Gillian Cowan; Adam J Mead; Sarah Filippi; Georg Bohn; Aristeidis Chaidos; Oliver Tunstall; Jerry K Y Chan; Mahesh Choolani; Phillip Bennett; Sailesh Kumar; Deborah Atkinson; Josephine Wyatt-Ashmead; Ming Hu; Michael P H Stumpf; Katerina Goudevenou; David O'Connor; Stella T Chou; Mitchell J Weiss; Anastasios Karadimitris; Sten Eirik Jacobsen; Paresh Vyas; Irene Roberts
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-08       Impact factor: 11.205

6.  Analysis of GATA1 mutations in Down syndrome transient myeloproliferative disorder and myeloid leukemia.

Authors:  Kate A Alford; Katarina Reinhardt; Catherine Garnett; Alice Norton; Katarina Böhmer; Christine von Neuhoff; Alexandra Kolenova; Emanuele Marchi; Jan-Henning Klusmann; Irene Roberts; Henrik Hasle; Dirk Reinhardt; Paresh Vyas
Journal:  Blood       Date:  2011-06-29       Impact factor: 22.113

7.  Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study A2971.

Authors:  Alan S Gamis; Todd A Alonzo; Robert B Gerbing; Joanne M Hilden; April D Sorrell; Mukta Sharma; Thomas W Loew; Robert J Arceci; Dorothy Barnard; John Doyle; Gita Massey; John Perentesis; Yaddanapudi Ravindranath; Jeffrey Taub; Franklin O Smith
Journal:  Blood       Date:  2011-08-17       Impact factor: 22.113

8.  Treatment and prognostic impact of transient leukemia in neonates with Down syndrome.

Authors:  Jan-Henning Klusmann; Ursula Creutzig; Martin Zimmermann; Michael Dworzak; Norbert Jorch; Claudia Langebrake; Arnulf Pekrun; Katarina Macakova-Reinhardt; Dirk Reinhardt
Journal:  Blood       Date:  2008-01-08       Impact factor: 22.113

9.  GATA1-mutant clones are frequent and often unsuspected in babies with Down syndrome: identification of a population at risk of leukemia.

Authors:  Irene Roberts; Kate Alford; Georgina Hall; Gaetan Juban; Helen Richmond; Alice Norton; Grant Vallance; Kelly Perkins; Emanuele Marchi; Simon McGowan; Anindita Roy; Gillian Cowan; Mark Anthony; Amit Gupta; John Ho; Sabita Uthaya; Anna Curley; Shree Vishna Rasiah; Timothy Watts; Richard Nicholl; Alison Bedford-Russell; Raoul Blumberg; Angela Thomas; Brenda Gibson; Chris Halsey; Pek-Wan Lee; Sunit Godambe; Connor Sweeney; Neha Bhatnagar; Anne Goriely; Peter Campbell; Paresh Vyas
Journal:  Blood       Date:  2013-09-10       Impact factor: 25.476

Review 10.  Transient Abnormal Myelopoiesis and AML in Down Syndrome: an Update.

Authors:  Neha Bhatnagar; Laure Nizery; Oliver Tunstall; Paresh Vyas; Irene Roberts
Journal:  Curr Hematol Malig Rep       Date:  2016-10       Impact factor: 3.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.